Hidradenitis Suppurativa

Description

Expect significant and much needed expansion of therapy options in the HS treatment sector. Will Abbvie's Humira/biosimilar adalimumab maintain its first-line position? How do KOLs assess anti-IL17 drugs and why do they say that UCB's Bimzelx has an edge on Novartis' Cosentyx? Why are experts enthusiastic about oral JAK inhibitors, despite safety concerns? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to the following KOL Bulletins via the Attachments area:

21 Sep 2023 KOL Bulletin -- Views on top-line results from the Phase IIb/III trial of Acelyrin's izokibep in moderate-to-severe HS

Executive summary (2)

Treatment algorithm (2)

Research objectives (1)

Marketed and off-label therapies (8)

Anti-tumour necrosis factor TNF agents (8)
- Humira (adalimumab; AbbVie) (8)
- Remicade (infliximab; Janssen/Merck & Co.)

Pipeline therapies (47)

IL-17 inhibitors (17)
- Cosentyx (secukinumab; Novartis) (8)
- Bimzelx (bimekizumab; UCB) (4)
- Izokibep (Acelyrin) (3)
- Sonelokimab (MoonLake Immunotherapeutics) (2)
IL-36 inhibitors (1)
- Spevigo (spesolimab; Boehringer Ingelheim) (1)
JAK inhibitors (12)
- Povorcitinib (INCB54707; Incyte) (6)
- Jakafi/Jakavi (ruxolitinib; Incyte) (3)
- Rinvoq (upadacitinib; AbbVie) (3)
JAK/TYK inhibitor (1)
- Brepocitinib (Priovant/Pfizer) (1)
Complement C5a inhibitors (4)
- Vilobelimab (InflaRx) and avacopan (Tavneos; Amgen/Vifor Fresenius) (4)
PDE4 inhibitor (3)
- Orismilast (UNION therapeutics) (3)
Chemokine (CXCR1/2) inhibitor (3)
- LY3041658 (Lilly) (3)
IL-1 inhibitor (3)
- Lutikizumab (ABT-981; AbbVie) (3)
Other mechanisms of action (3)
- Key insights summary (3)

Treatment dynamics for the management of HS

Key insights summary
- Multiple drug approvals will provide KOLs with better treatment options for HS: anti-IL17 therapies will become firmly established